Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

NCT02212561 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Myelodysplastic Syndrome (MDS)
Mixed Phenotype Acute Leukemia (MPAL)

Interventions

DRUG: Selinexor
DRUG: Fludarabine
DRUG: Cytarabine
DRUG: methotrexate/hydrocortisone/cytarabine

Sponsor

St. Jude Children's Research Hospital

Collaborators

[object Object]